Meanwhile, Cosmo Pharmaceutical Business IP Manager Lidija Petovar said that Novo Nordisks move is purely a strategic decision and very common practice in the pharmaceutical industry
Zepbound (Tirzepatide) Zepbound is a once-weekly injection that targets two hormones for substantial weight loss results
GLP-1 medications are not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN2 (Multiple Endocrine Neoplasia syndrome type 2), a history of pancreatitis, or anyone currently pregnant or breastfeeding
Improper use may cause: Severe nausea Vomiting Dehydration Muscle loss Gallstones Pancreatitis Nutritional deficiencies Low blood sugar (in diabetic patients) In rare cases, serious complications may occur if patients already have underlying endocrine or gastrointestinal disorders
The deeper solution is rewiring the mindset, habits, coping patterns, lifestyle, and identity that drive long-term weight